13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674712
Total reported value
$1.1B
$1.1B
42 檔
57.2%
As reported in its official Q2 2024 Form 13F filing, Vivo Capital, LLC's tracked investment portfolio stood at $1.1B with 42 total positions.
During Q2 2024, Vivo Capital, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including SLNOEUR, GERN, HRMY) accounted for 57.2% of total reported equity market value during Q2 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 27.58% | -0.82% | EXIT | |
| 2 | GERN | Geron CORP | Stock-Other | 10.66% | -0.06% | — | |
| 3 | HRMY | Harmony Biosciences Holdings | Stock-Other | 7.26% | — | — | |
| 4 | SVA | Sinovac Biotech Ltd. | Stock-Other | 7.05% | +0.32% | — | |
| 5 | DYN | Dyne Therapeutics Inc | Stock-Other | 5.33% | +0.81% | — | |
| 6 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 5.16% | — | — | |
| 7 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 4.74% | — | -1.67% | |
| 8 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 3.89% | -5.85% | EXIT | |
| 9 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 2.35% | +0.07% | — | |
| 10 | VRDN | Viridian Therapeutics Inc | Stock-Other | 2.02% | -0.27% | EXIT | |
| 11 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.96% | — | — | |
| 12 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.94% | — | — | |
| 13 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 1.87% | -0.06% | — | |
| 14 | COGT | Cogent Biosciences Inc | Stock-Other | 1.75% | -1.35% | EXIT | |
| 15 | ERAS | Erasca Inc | Stock-Other | 1.47% | -9.44% | — | |
| 16 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 1.42% | — | — | |
| 17 | DCTH | Delcath Systems Inc | Stock-Other | 1.29% | — | — | |
| 18 | RZLT | Rezolute Inc | Stock-Other | 1.11% | — | — | |
| 19 | CELC | Celcuity Inc | Stock-Other | 0.92% | — | — | |
| 20 | SERA | Sera Prognostics Inc-a | Stock-Other | 0.90% | -0.01% | — | |
| 21 | CMPS | Compass Pathways PLC | Stock-Other | 0.90% | -0.09% | EXIT | |
| 22 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 0.85% | — | — | |
| 23 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 0.83% | -0.12% | +49.43% | |
| 24 | RGLS | Regulus Therapeutics Inc | Stock-Other | 0.82% | — | — | |
| 25 | ABEO | Abeona Therapeutics Inc | Stock-Other | 0.72% | — | — | |
| 26 | TRML | Tourmaline Bio Inc | Stock-Other | 0.70% | — | — | |
| 27 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.70% | — | — | |
| 28 | IOBTQ | Io Biotech Inc | Stock-Other | 0.67% | — | — | |
| 29 | TIL | Instil Bio Inc | Stock-Other | 0.59% | +0.01% | +0.00% | |
| 30 | ✓ | Engene Holdings Inc | Stock-Other | 0.59% | — | — | |
| 31 | VSTM | Verastem Inc | Stock-Other | 0.42% | — | — | |
| 32 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.33% | -2.65% | — | |
| 33 | ALLKGUSD | Allakos Inc | Stock-Other | 0.28% | — | — | |
| 34 | BOLT1EUR | Bolt Biotherapeutics Inc | Stock-Other | 0.24% | — | — | |
| 35 | ✓ | Stock-Other | 0.16% | — | — | ||
| 36 | ✓ | Aligos Therapeutics Inc | Stock-Other | 0.11% | — | — | |
| 37 | CDXS | Codexis Inc | Stock-Other | 0.11% | — | — | |
| 38 | ✓ | Dbv Technologies S A | Stock-Other | 0.10% | — | — | |
| 39 | AVU0 | Adverum Biotechnologies Inc | Stock-Other | 0.08% | — | -44.44% | |
| 40 | WHWK | Whitehawk Therapeutics Inc | Stock-Other | 0.07% | — | — | |
| 41 | QTTB | Q32 Bio Inc | Stock-Other | 0.03% | — | -94.44% | |
| 42 | DTIL | Precision Biosciences Inc | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Vivo Capital, LLC reported a total U.S. public equity portfolio value of $1.1B across 42 disclosed positions in Q2 2024.
During Q2 2024, Vivo Capital, LLC's top holdings by market value included SLNOEUR (27.6%)、GERN (10.7%)、HRMY (7.3%). The largest single position, SLNOEUR, represented 27.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q2 2024, Vivo Capital, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.